KPTI

SEC source: 0001209191-23-014861 · doc4.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,926

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024.

F2 · balance_after: Includes 1,977 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2022.

SEC source: 0001209191-23-014865 · doc4.xml · nonDerivative · entry 1

Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,000

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024.

SEC source: 0001209191-23-014838 · doc4.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 856,655

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024.

SEC source: 0001209191-23-014873 · doc4.xml · nonDerivative · entry 1

Rangwala Reshma · CIK 0001825322 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,000

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024.

SEC source: 0001209191-23-014872 · doc4.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,131

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024.

SEC source: 0001209191-23-014869 · doc4.xml · nonDerivative · entry 1

Mitchener Stephen · CIK 0001774519 · SVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,670

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024.

F2 · balance_after: Includes 2,147 shares and 1,977 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on April 30, 2022 and October 31, 2022, respectively.

SEC source: 0001209191-23-014843 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 256,566

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024.

SEC source: 0001209191-23-014078 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,566

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-23-010509 · doc4.xml · nonDerivative · entry 3

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,131

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-23-010509 · doc4.xml · nonDerivative · entry 2

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,327

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-23-010509 · doc4.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,335

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-23-007772 · doc4.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 604,655

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-23-007775 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,368

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-23-002052 · doc4.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 608,605

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-22-060041 · doc4.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 612,527

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-22-056152 · doc4.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 616,017

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-22-052726 · doc4.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 619,510

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-22-049255 · doc4.xml · nonDerivative · entry 2

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 622,998

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-22-049255 · doc4.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 626,461

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-22-048395 · doc4.xml · derivative · entry 2

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2032-08-30

F2 · derivative.exercise_date: This option was granted on August 31, 2022 pursuant to the Plan. The shares underlying this option vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024.

SEC source: 0001209191-22-048395 · doc4.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,949

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024.

SEC source: 0001209191-22-048396 · doc4.xml · derivative · entry 2

Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2032-08-30

F2 · derivative.exercise_date: This option was granted on August 31, 2022 pursuant to the Plan. The shares underlying this option vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024.

SEC source: 0001209191-22-048396 · doc4.xml · nonDerivative · entry 1

Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,000

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024.

SEC source: 0001209191-22-048394 · doc4.xml · derivative · entry 2

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2032-08-30

F2 · derivative.exercise_date: This option was granted on August 31, 2022 pursuant to the Plan. The shares underlying this option vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024.

SEC source: 0001209191-22-048394 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 168,509

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024.

SEC source: 0001209191-22-048397 · doc4.xml · derivative · entry 2

Mitchener Stephen · CIK 0001774519 · SVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2032-08-30

F2 · derivative.exercise_date: This option was granted on August 31, 2022 pursuant to the Plan. The shares underlying this option vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024.

SEC source: 0001209191-22-048397 · doc4.xml · nonDerivative · entry 1

Mitchener Stephen · CIK 0001774519 · SVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,546

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024.

SEC source: 0001209191-22-045718 · doc4.xml · derivative · entry 2

Greene Barry E · CIK 0001291963 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,576 shares

Expires 2023-01-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 14, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-045718 · doc4.xml · nonDerivative · entry 1

Greene Barry E · CIK 0001291963 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,606

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-044561 · doc4.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 626,477

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-22-041774 · doc4.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 628,791

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-22-036812 · doc4.xml · nonDerivative · entry 2

Cheng Sohanya Roshan · CIK 0001865796 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,949

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-22-036812 · doc4.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,434

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0000899243-22-021957 · doc4.xml · nonDerivative · entry 6

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 16,673

F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000899243-22-021957 · doc4.xml · nonDerivative · entry 5

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,707,549

F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000899243-22-021957 · doc4.xml · nonDerivative · entry 4

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 16,686

F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000899243-22-021957 · doc4.xml · nonDerivative · entry 3

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,708,843

F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000899243-22-021957 · doc4.xml · nonDerivative · entry 2

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 18,731

F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000899243-22-021957 · doc4.xml · nonDerivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,918,298

F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000899243-22-021477 · doc4.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 630,906

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0000899243-22-021234 · doc4.xml · nonDerivative · entry 2

Mason Michael · CIK 0001514291 · EVP, CFO, Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,509

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0000899243-22-021234 · doc4.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO, Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,512

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-22-030970 · doc4.xml · derivative · entry 1

Honig Peter · CIK 0001484780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,995

Underlying: Common Stock · 10,995 shares

Expires 2032-05-18

F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 19, 2023 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc.

SEC source: 0001209191-22-030953 · doc4.xml · derivative · entry 1

Greene Barry E · CIK 0001291963 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,900

Underlying: Common Stock · 23,900 shares

Expires 2032-05-18

F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 19, 2023 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc.

SEC source: 0001209191-22-030983 · doc4.xml · derivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,900

Underlying: Common Stock · 23,900 shares

Expires 2032-05-18

F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 19, 2023 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc.

SEC source: 0001209191-22-030956 · doc4.xml · derivative · entry 1

BOHLIN GAREN G · CIK 0001254705 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,900

Underlying: Common Stock · 23,900 shares

Expires 2032-05-18

F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 19, 2023 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc.

SEC source: 0001209191-22-030986 · doc4.xml · derivative · entry 1

Schor Chen · CIK 0001340875 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,900

Underlying: Common Stock · 23,900 shares

Expires 2032-05-18

F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 19, 2023 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc.

SEC source: 0001209191-22-030978 · doc4.xml · derivative · entry 1

Oliger Christy J. · CIK 0001822092 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,900

Underlying: Common Stock · 23,900 shares

Expires 2032-05-18

F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 19, 2023 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc.

SEC source: 0001209191-22-030972 · doc4.xml · derivative · entry 1

Mirza Mansoor Raza · CIK 0001588389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,900

Underlying: Common Stock · 23,900 shares

Expires 2032-05-18

F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 19, 2023 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc.

SEC source: 0001209191-22-027344 · doc4.xml · nonDerivative · entry 2

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 633,448

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.